menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free
ReachMD Faculty

Public Profile

Felicia Cosman, MD
Felicia Cosman, MD
    Felicia Cosman, M.D., is the Medical Director of the Clinical Research Center at Helen Hayes Hospital and Professor of Medicine at Columbia University College of Physicians and Surgeons in New York. Dr. Cosman is a graduate of Cornell University and Stony Brook Medical School. She received her internal medicine training and completed her endocrinology fellowship at Columbia Presbyterian Medical Center in New York City. Dr. Cosman’s research includes studies on the causes of osteoporosis and how estrogen, SERMS, vitamin D, bisphosphonates, and other therapies work as treatments for osteoporosis. She has also studied the causes of stress fractures and factors influencing the acquisition of peak bone mass. In addition, Dr. Cosman has been involved in many research studies evaluating the effectiveness and safety of investigational osteoporosis medications. A major research focus over the last decade has been on the use of bone building (anabolic) medications, alone and in combination or sequence with antiresorptive agents, and in novel cyclic regimens for the treatment of patients with severe osteoporosis. She has been a major contributor to the areas of vertebral fracture identification and goal directed osteoporosis treatment. She is the recipient of multiple research grants from the National Institutes of Health, the Department of Defense, the National Multiple Sclerosis Society, and multiple pharmaceutical companies. Dr. Cosman has published over 140 peer-reviewed articles in the osteoporosis field. Most recently, she was selected as Editor-in-Chief of Osteoporosis International. Osteoporosis International (OI) is an international multi-disciplinary journal, a joint initiative of the International Osteoporosis Foundation and the US National Osteoporosis Foundation.
    Schedule18 Apr 2024